CLIFTON, NJ / ACCESSWIRE / January 5, 2016 / mPhase Technologies, Inc. (OTC: XDSL) (http://www.mPhaseTech.com) is pleased to announced that the U.S. Patent and Trademark Office has awarded a Notice of Allowance of a Patent covering a "new and useful" Drug Delivery System said Ronald A. Durando, the Company's Chairman, President and CEO.
Image: https://www.accesswire.com/uploads/mPhase%20-%20Smart%20Battery%20with%2012%20droplets%20and%20logo_%20in%205.12.11%20Press%20Release.jpg
The invention allows a drug delivery system to automatically dispense a pre-set dosage of a drug or medication. "Many individuals require a routine application of drugs. For instance, individuals with diabetes require routine injections of insulin to maintain proper blood sugar levels. People with various skin conditions require a routine application of medicated creams," Mr. Durando explains.
"Individuals have been required to manually measure out the required amount of medication, which is highly susceptible to human error, particularly in individuals with impacted mental states. Hiring a health professional to handle this on a day-to-day basis can be cost-prohibitive," mPhase Technologies CEO explains. "That is why there is a need for a new and improved drug delivery system to automatically dispense a pre-set dosage of medication."
The invention includes one or more reservoirs, hermetically sealed with the correct amount of medication and covered by a membrane, which can be breached or rendered permeable in several different ways when a dose of the medication needs to be delivered.
"We believe this new invention will be a major positive for the Company and its shareholders," Mr. Durando said. The Company also announced that it has retained E & E Communications, Texas, to assist its investor relations efforts.
About mPhase Technologies, Inc.: mPhase Technologies Inc. is a publicly traded company pioneering a revolutionary Smart Surface technology enabled by breakthroughs in nanotechnology, MEMS processing and microfluidics. Our Smart Surface technology has potential applications in drug delivery systems, lab-on-a-chip analytic systems, self-cleaning systems, liquid and chemical sensor systems and filtration systems.
Forward-Looking Statements: Certain matters discussed in this press release may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; acceptance of the Company's products in the market; the Company's success in technology and product development; the Company's ability to execute its business model and strategic plans; and all the risks and related information described from time to time in the Company's SEC filings, including the financial statements and related information contained in the Company's SEC Filing. mPhase Technologies assumes no obligation to update the information in this release.
Contact:
Paul Knopick
pknopick@eandecommunications.com
940.262.3584
SOURCE: mPhase Technologies, Inc.